Literature DB >> 22971538

Concurrent audit of fresh frozen plasma: experience of a tertiary care hospital.

Sangeeta Pahuja1, Neha Sethi, Smita Singh, Sunita Sharma, Manjula Jain, Shivani Kushwaha.   

Abstract

UNLABELLED: Fresh frozen plasma (FFP) transfusion is among the highest risk of all blood component transfusions and also the most inappropriately used blood component. All these factors have impact on safety, economy, and work burden.
OBJECTIVE: To assess the utilization of FFP in a tertiary care hospital.
METHODS: Concurrent audit was conducted manually over the period of 4 months from April 2010 to July 2010. Patient's age, sex, clinical diagnosis, indication for FFP transfusion, and coagulation profile were noted. Data were analysed and episodes of transfusion were divided into appropriate and inappropriate. Requests were further classified according to the requesting department, clinical diagnosis, and coagulation profile.
RESULTS: A total of 1763 units of FFP were transfused to 560 patients in 877 episodes of requisition. Out of 877 episodes, about 686 (78.2%) requests were found to be inappropriate. Highest number of FFP requisitions was received from department of paediatrics and paediatric surgery (580 episodes). Most inappropriate requests were received from the department of orthopaedics (88.9%) and paediatrics (80.17%). The most common indication for FFP transfusion was surgical/traumatic bleeding/massive transfusion (40.9%) in which 68.5% requests were inappropriate. Out of 686 inappropriate episodes, the most common cause was in setting of normal or mildly altered coagulation profile irrespective of bleeding status of patient. DISCUSSION: Inadvertent use of FFP is a major problem and guidelines are not strictly adhered to. Concurrent audit of FFP use needs to be done to make appropriate interventions to prevent misuse of this valuable commodity.

Entities:  

Mesh:

Year:  2012        PMID: 22971538     DOI: 10.1179/1607845412Y.0000000019

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  6 in total

1.  Use of fresh-frozen plasma in 2012 at the Fondazione Ca' Granda Hospital of Milan: assessment of appropriateness using record linkage techniques applied to data routinely recorded in various hospital information systems.

Authors:  Monica Lanzoni; Barbara Olivero; Andrea Artoni; Maurizio Marconi; Elisabetta Raspollini; Silvana Castaldi
Journal:  Blood Transfus       Date:  2017-06-19       Impact factor: 3.443

2.  A retrospective audit to evaluate the appropriateness and rationalization of Fresh Frozen Plasma usage in a tertiary care hospital.

Authors:  Sudeep Kumar; Neerja Kushwaha; Akshaya Tomar; Joseph Philip; Amit Kumar Biswas
Journal:  Med J Armed Forces India       Date:  2021-07-30

3.  Prophylactic plasma transfusion for patients undergoing non-cardiac surgery.

Authors:  Jonathan Huber; Simon J Stanworth; Carolyn Doree; Marialena Trivella; Susan J Brunskill; Sally Hopewell; Kirstin L Wilkinson; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2017-08-17

4.  Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures.

Authors:  Jonathan Huber; Simon J Stanworth; Carolyn Doree; Patricia M Fortin; Marialena Trivella; Susan J Brunskill; Sally Hopewell; Kirstin L Wilkinson; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2019-11-28

5.  The evaluation of the audit of Fresh-Frozen Plasma (FFP) usage in emergency department.

Authors:  Emine Emektar; Seda Dagar; Seref Kerem Corbacioglu; Huseyin Uzunosmanoglu; Mehmet Veysel Oncul; Yunsur Cevik
Journal:  Turk J Emerg Med       Date:  2016-08-20

6.  Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks.

Authors:  Nicholas H Saadah; Martin R Schipperus; Johanna C Wiersum-Osselton; Marian G van Kraaij; Camila Caram-Deelder; Erik A M Beckers; Anja Leyte; Jan M M Rondeel; Karen M K de Vooght; Floor Weerkamp; Jaap Jan Zwaginga; Johanna G van der Bom
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.